First National Trust Co Has $25.40 Million Holdings in Eli Lilly and Company $LLY

First National Trust Co cut its position in Eli Lilly and Company (NYSE:LLY) by 2.5% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 32,588 shares of the company’s stock after selling 823 shares during the quarter. Eli Lilly and Company comprises 0.9% of First National Trust Co’s portfolio, making the stock its 22nd biggest holding. First National Trust Co’s holdings in Eli Lilly and Company were worth $25,403,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. PNC Financial Services Group Inc. raised its holdings in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after buying an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. raised its stake in Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares in the last quarter. Wellington Management Group LLP raised its stake in Eli Lilly and Company by 0.6% during the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after acquiring an additional 81,587 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Eli Lilly and Company by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock worth $4,808,443,000 after purchasing an additional 682,203 shares in the last quarter. Finally, Nuveen LLC bought a new stake in shares of Eli Lilly and Company during the first quarter worth $4,613,912,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on LLY shares. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Cantor Fitzgerald set a $925.00 price target on Eli Lilly and Company and gave the stock an “overweight” rating in a report on Thursday, October 9th. Morgan Stanley cut their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, BMO Capital Markets raised their price objective on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the company an “outperform” rating in a research note on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $938.61.

Eli Lilly and Company Stock Up 0.0%

LLY opened at $825.74 on Tuesday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company’s 50-day moving average is $770.54 and its 200 day moving average is $769.08. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $935.63. The firm has a market capitalization of $781.53 billion, a P/E ratio of 53.97, a PEG ratio of 1.23 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the firm earned $3.92 earnings per share. The firm’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares of the company’s stock, valued at $87,331,504. The trade was a 0.73% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock valued at $2,894,841 in the last ninety days. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.